Showing results (1-10 of 75) with videos related to
Sort By:
Pageof 8
Seminars in Oncology|October 31, 2001
Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancerM E Taplin, G J Bubley, B Rajeshkumar, et al.Cancer Research|June 11, 1999
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonistM E Taplin, G J Bubley, Y J Ko, et al.Somatic Cell and Molecular Genetics|March 1, 1987
Effects of Bloom's syndrome fibroblasts on genetic recombination and mutagenesis of herpes simplex virus type 1G J Bubley, L E SchnipperHematology/Oncology Clinics of North America|June 1, 1996
Treatment of metastatic prostate cancer. Lessons from the androgen receptorG J Bubley, S P BalkClinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancerY J Ko, E J Small, F Kabbinavar, et al.Antimicrobial Agents and Chemotherapy|April 1, 1986
Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and mutagenesis of herpes simplex virus type 1G J Bubley, C S Crumpacker, L E SchnipperMolecular Carcinogenesis|January 1, 1991
Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cellsG J Bubley, B P Ashburner, B A TeicherCancer Research|May 1, 1984
Repair of DNA following incorporation of 1-beta-D-arabinofuranosylcytosine into herpes simplex virus type 1G J Bubley, C S Crumpacker, L E SchnipperPageof 8